Low–Density Lipoprotein Removal Methods by Membranes and Future Perspectives

Matsuda, Yukihiro; Malchesky, Paul S.; Nosé, Yukihiko

doi:10.1111/j.1525-1594.1996.tb04458.x

Cited by 12 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The formation of a cryogel, which can occlude the larger membrane pores and thereby decrease LDL‐HDL selectivity, was successfully prevented by the heating system. Overall sieving characteristics were also improved with the higher temperature (16–18).…”

Section: Mean Percentage Reduction Of Plasma Proteins With Different mentioning

confidence: 97%

From Membrane Differential Filtration to Lipidfiltration: Technological Progress in Low‐density Lipoprotein Apheresis

et al. 2003

View full text Add to dashboard Cite

Extracorporeal low-density lipoprotein (LDL) apheresis is an established and highly effective therapy for patients with familial hypercholesterolemia (FH) not adequately responding to diet and drug therapy alone. Based on different methodology, five treatment options of LDL apheresis are available and in widespread practical use in Germany. All methods are safe and demonstrate equivalent efficacy of reducing LDL cholesterol with respect to the single apheresis session as well as during long-term treatment. Owing to methodological properties all methods also exhibit characteristics of additional plasma protein elimination, which do not impair, but in part, increase the beneficial therapeutic effect of LDL apheresis. Fibrinogen reduction has to be mentioned as an example. The lipidfiltration system is based on plasmafiltration previously named membrane differential filtration (MDF), synonymous with double filtration plasmapheresis (DFPP). The new term lipidfiltration was the result of technological progress leading to a significant improvement of the efficiency. The system consists of a novel lipid filter with enhanced sieving characteristics and capacity, and is completed by an enhanced therapy machine with an optimized heating unit.

show abstract

Section: Mean Percentage Reduction Of Plasma Proteins With Different mentioning

confidence: 97%

From Membrane Differential Filtration to Lipidfiltration: Technological Progress in Low‐density Lipoprotein Apheresis

et al. 2003

View full text Add to dashboard Cite

show abstract

“…This system prevents not only cryogel formation but also plugging and poor plasma filter performance. The procedure enhances the performance of Evaflux 4 A and 5 A plasma filters (Kuraray, Osaka, Japan) used in DFPP (11). Thermofiltration effectively and selectively removes LDL cholesterol while retaining plasma components such as albumin and HDL cholesterol.…”

Section: Procedures For Low‐density Lipoprotein Apheresismentioning

confidence: 99%

Low‐density Lipoprotein Apheresis in the Treatment of Peripheral Arterial Disease

Kawashima

2003

Ther Apher Dial

View full text Add to dashboard Cite

Low-density lipoprotein (LDL) apheresis is performed in patients with homozygous familial hyper-cholesterolemia who lack LDL receptors and with heterozygous familial hypercholesterolemia who are LDL receptor deficient with documented, symptomatic coronary artery disease who are resistant to diet changes and maximum drug therapy. LDL apheresis can reduce or abolish anginal symptoms and improve coronary lesions. Several reports reveal the improvement of insufficient peripheral blood flow. By extensively removing blood LDL and changing coagulation factors and various vasoactive substances, LDL apheresis improves blood rheology and thereby peripheral circulation. It seems worth trying on all patients with arteriosclerotic lesions, even if they are normocholesterolemic.

show abstract

“…The sICAM-1 and sVCAM-1 are released from the cell membrane by cleavage due to proteinase. The sieving coefficient of substances that have a 60 kilodalton molecu- lar weight is more than 0.9 in a 5 A membrane (11,12). Therefore, it is difficult to remove these substances by DFPP treatment using a 5 A plasma fractionator membrane.…”

Section: Discussionmentioning

confidence: 99%

Double Filtration Plasmapheresis Maintains Normal Adhesion Molecule Levels

Yamane

Matsugane

Motohashi

et al. 1998

Therapeutic Apheresis

View full text Add to dashboard Cite

Levels of plasma soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), and von Willebrand factor (vWF) increase in patients with peripheral vascular or ischemic heart disease. These factors are related to the progression of atherosclerosis. Furthermore, these substances and thrombomodulin (TM) are indicators for assessing the degree of damage to the endothelium. To evaluate the effect of double filtration plasmapheresis (DFPP) on these molecules, the plasma levels of vWF, sICAM-1, sVCAM-1, and TM were measured in 4 familial hypercholesterolemia (FH) patients who underwent treatment with DFPP at 2 week intervals for more than 3 years. The levels of sVCAM-1 and sICAM-1 in hypercholesterolemia patients with ischemic heart disease as a control was 773 +/- 109 and 334 +/- 82 ng/ml. These values were higher than the normal value. In the FH patients who underwent DFPP treatment, the average sICAM-1 levels were 221 +/- 47 and 197 +/- 36 ng/ml before and after, respectively. The average sVCAM-1 levels were 601 +/- 87 and 486 +/- 60 ng/ml. There were no significant differences between the pre- and post-DFPP values. The activities of plasma vWF before and after DFPP treatment were 158 +/- 23 and 45 +/- 9%. The levels of plasma TM before and after treatment were 3.0 +/- 0.3 and 3.4 +/- 0.5 FU/ml. From these results, it is suggested that DFPP treatment does not damage the endothelium and may prevent the progression of atherosclerosis by removing the substances that induce the production of sICAM-1 and sVCAM-1 due to long-term treatment.

show abstract

Low–Density Lipoprotein Removal Methods by Membranes and Future Perspectives

Cited by 12 publications

References 28 publications

From Membrane Differential Filtration to Lipidfiltration: Technological Progress in Low‐density Lipoprotein Apheresis

From Membrane Differential Filtration to Lipidfiltration: Technological Progress in Low‐density Lipoprotein Apheresis

Low‐density Lipoprotein Apheresis in the Treatment of Peripheral Arterial Disease

Double Filtration Plasmapheresis Maintains Normal Adhesion Molecule Levels

Contact Info

Product

Resources

About